Prof. Dr. med. Peter Fasching



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk (2025) Müller V, Hörner M, Thill M, Banys-Paluchowski M, Schmatloch S, Fasching P, Harbeck N, et al. Journal article The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study (2025) Schneeweiss A, Fasching P, Thill M, van Mackelenbergh M, Marme F, Tesch H, Fehm TN, et al. Journal article Update Breast Cancer 2024 Part 3 – Patients with Advanced Stage Breast Cancer (2025) Lüftner D, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, et al. Journal article, Review article Update Breast Cancer 2024 Part 2 – Patients with Early Stage Breast Cancer (2025) Janni W, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, et al. Journal article, Review article Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification (2025) Galas K, Gleitsmann M, Rey J, Solbach C, Witzel I, Karn T, Schmatloch S, et al. Journal article Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study (2025) Fasching P, Schmatloch S, Hauke J, Rey J, Jackisch C, Klare P, Link T, et al. Journal article Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes (2025) Collin LJ, Cushing-Haugen KL, Terry KL, Goode EL, Wu AH, Harris HR, Sasamoto N, et al. Journal article BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2-Breast Cancer Treated with Endocrine Therapy with or Without Palbociclib: A Secondary PENELOPE-B Study Analysis (2025) Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, et al. Journal article Fully automatic HER2 tissue segmentation for interpretable HER2 scoring (2025) Öttl M, Steenpaß J, Wilm F, Qiu J, Rübner M, Lang-Schwarz C, Taverna C, et al. Journal article Improving quality of care for cancer patients through oncological second opinions in a Comprehensive Cancer Center: adherence to second-opinion therapy recommendations (2025) Schulmeyer C, Fasching P, Beckmann M, Häberle L, Golcher H, Goebell P, Pöschke P, Emons J Journal article